Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Randomized, Double-Blind, Placebo-Controlled Study of CR8020 in an Influenza Challenge Model
2013-002185-39Phase 2Completed
- Sponsor
- Crucell
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in influenza comparing CR8020 arm with Placebo arm (2 arms). Primary endpoint: AUC of nasal viral load. Started Jun 2013; status: completed.
02
Drugs
CR8020
03
Conditions
influenza
Beyond the preview
Go deeper on 2013-002185-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002185-39.